Sahlgrenska university hospital, Department of Clinical Microbiology, Gothenburg, Sweden.
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
APMIS. 2020 May;128(5):387-389. doi: 10.1111/apm.13036.
Tumor tissue often has an insufficient nutritional supply, in part due to compression of the vascular network from an increased interstitial fluid pressure. We have shown that the antisecretory factor peptide AF-16 can reduce this pressure in experimental rat breast tumors. In this work we studied if AF-16 administration opened up to an increased vascular volume in these tumors. Sprague-Dawley rats were given dimethylbenxanthracene and developed mammary tumors which were studied. Evans Blue was used as an intravascular volume indicator. Under anesthesia the rats were given AF-16 or solvent intranasally, and Evans Blue was injected i.v. 45 min later. Tumors and various organs were dissected and Evans Blue was extracted and colorimetrically quantified. Tumors had a significantly higher vascular volume after AF-16 administration as compared to other organs. Liver and renal vascular volumes were also increased but to a lesser degree than in the tumors. The results indicate that AF16 could be a candidate for increasing vascular access for chemotherapy in cancer therapy.
肿瘤组织的营养供应常常不足，部分原因是由于间质液压力升高导致血管网络受压。我们已经表明，抗分泌因子肽 AF-16 可以降低实验性大鼠乳腺肿瘤中的这种压力。在这项工作中，我们研究了 AF-16 给药是否会增加这些肿瘤中的血管容积。给予 Sprague-Dawley 大鼠二甲苯蒽并发展乳腺肿瘤进行研究。伊文思蓝被用作血管内容积指示剂。在麻醉下，大鼠经鼻内给予 AF-16 或溶剂，45 分钟后静脉内注射伊文思蓝。将肿瘤和各种器官解剖出来，并提取伊文思蓝并进行比色定量。与其他器官相比，AF-16 给药后肿瘤的血管容积显著增加。肝和肾的血管容积也增加，但程度低于肿瘤。结果表明，AF16 可能是增加癌症治疗中化疗血管通路的候选药物。
